These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27805837)

  • 1. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
    Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
    Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-Angiotensin System Inhibitors Might Help to Reduce the Development of Symptomatic Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer.
    Bracci S; Valeriani M; Agolli L; De Sanctis V; Maurizi Enrici R; Osti MF
    Clin Lung Cancer; 2016 May; 17(3):189-97. PubMed ID: 26427647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images.
    Yamamoto T; Kadoya N; Sato Y; Matsushita H; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Morishita Y; Katagiri Y; Sato K; Ito K; Takeda K; Jingu K
    Clin Lung Cancer; 2018 Jan; 19(1):e85-e90. PubMed ID: 28655592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
    Matsuo Y; Shibuya K; Nakamura M; Narabayashi M; Sakanaka K; Ueki N; Miyagi K; Norihisa Y; Mizowaki T; Nagata Y; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e545-9. PubMed ID: 22436782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
    Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
    Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.
    Ryckman JM; Baine M; Carmicheal J; Osayande F; Sleightholm R; Samson K; Zheng D; Zhen W; Lin C; Zhang C
    Radiat Oncol; 2020 Feb; 15(1):33. PubMed ID: 32054487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.
    Harder EM; Park HS; Chen ZJ; Decker RH
    Pract Radiat Oncol; 2016; 6(6):e353-e359. PubMed ID: 27156424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Muller DA; Dutta SW; Aliotta E; Sanders JC; Wijesooriya K; Watkins WT; Larner JM
    Clin Lung Cancer; 2021 May; 22(3):234-241. PubMed ID: 32690439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
    Takeda A; Ohashi T; Kunieda E; Sanuki N; Enomoto T; Takeda T; Oku Y; Shigematsu N
    Br J Radiol; 2012 May; 85(1013):636-42. PubMed ID: 22253343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
    Parker SM; Siochi RA; Wen S; Mattes MD
    Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer.
    Liu Y; Wang W; Shiue K; Yao H; Cerra-Franco A; Shapiro RH; Huang KC; Vile D; Langer M; Watson G; Bartlett G; Ai H; Sheski F; Jin JY; Zellars R; Fu P; Lautenschlaeger T; Kong FS
    Radiother Oncol; 2021 Mar; 156():231-238. PubMed ID: 33096168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
    Ren C; Ji T; Liu T; Dang J; Li G
    Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
    Takeda A; Kunieda E; Ohashi T; Aoki Y; Oku Y; Enomoto T; Nomura K; Sugiura M
    Chest; 2012 Apr; 141(4):858-866. PubMed ID: 21885726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
    Baker R; Han G; Sarangkasiri S; DeMarco M; Turke C; Stevens CW; Dilling TJ
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):190-5. PubMed ID: 22929858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
    Harder EM; Park HS; Nath SK; Mancini BR; Decker RH
    Pract Radiat Oncol; 2015; 5(6):e643-9. PubMed ID: 26412341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.
    Takeda A; Ohashi T; Kunieda E; Enomoto T; Sanuki N; Takeda T; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):685-90. PubMed ID: 20510193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.
    Ueyama T; Arimura T; Takumi K; Nakamura F; Higashi R; Ito S; Fukukura Y; Umanodan T; Nakajo M; Koriyama C; Yoshiura T
    Br J Radiol; 2018 Jun; 91(1086):20170453. PubMed ID: 29565649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
    Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.